Apliko Inc leverages generative AI to automate the discovery of materials, chemicals, catalysts, and pharmaceuticals, significantly accelerating the research and development timeline. This technology reduces the time and costs associated with traditional experimental methods, enhancing efficiency in material innovation.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional research and development of new materials, chemicals, catalysts, and pharmaceuticals relies on time-consuming and expensive experimental methods. This slows down the pace of innovation and increases the costs associated with discovering novel compounds and materials.
Solution
Apliko Inc. offers an AI-as-a-service platform that leverages generative AI to accelerate the discovery of new materials and compounds. Their technology automates core research workflows across biology, chemistry, and materials science, significantly reducing the time and cost associated with traditional R&D. The platform empowers researchers to explore a wider range of possibilities and identify promising candidates more efficiently. Apliko's AI agents can be used to design novel materials with specific properties, optimize chemical reactions, and identify potential drug candidates.
Target Audience
Apliko's primary customers are researchers, scientists, and engineers in the fields of materials science, chemistry, and pharmaceuticals, as well as organizations involved in biomedical research and clinical decision support.
Features
- AI-powered agent for automating research workflows in biology, chemistry, and materials science
- Generative AI models for designing novel materials, chemicals, and pharmaceuticals
- RAG-enabled AI Copilot for Clinical Decision Support
- Multi-agent shopping companion that delivers voice-activated, taste-aware curation of affordable health, fashion, and sustainable products
- Multimodal machine learning training, evaluation, and inference platform for biomedical foundation models